1
|
Nouwens SPH, Marceta SM, Bui M, van Dijk DMAH, Groothuis-Oudshoorn CGM, Veldwijk J, van Til JA, de Bekker-Grob EW. The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review. PHARMACOECONOMICS 2025:10.1007/s40273-025-01495-y. [PMID: 40397369 DOI: 10.1007/s40273-025-01495-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/30/2025] [Indexed: 05/22/2025]
Abstract
INTRODUCTION Stakeholder preference evaluations are increasingly emphasized in healthcare policy and health technology assessment. Discrete choice experiments (DCEs) are the most common method for quantifying preferences among patients, the public, and healthcare professionals. While prior reviews (1990-2017) have examined DCE trends, no comprehensive synthesis exists for studies published since 2018. This updated review (2018-2023) provides critical insights into evolving methodologies and global trends in health-related DCEs. METHODS A systematic search (2018-2023) of Medline, Embase, and Web of Science identified relevant studies. Studies were screened for inclusion and data were extracted, including details on DCE design and analysis. To enable trend comparisons, the search strategy and extraction items aligned with previous reviews. RESULTS Of 2663 identified papers, 1279 met the inclusion criteria, reflecting a significant rise in published DCEs over time. DCEs were conducted globally, with a remarkable increase in publications from Asia and Africa compared with previous reviews. Experimental designs and econometric models have advanced, continuing prior trends. Notably, most recent DCEs were administered online. DISCUSSION The rapid growth of DCE applications underscores their importance in health research. While the methodology is advancing rapidly, it is crucial that researchers provide full transparency in reporting their methods, particularly in detailing experimental designs and validity tests, which are too often overlooked. Key recommendations include improving reporting of experimental designs, applying validity tests, following good practices for presenting benefit-risk attributes, and adopting open science practices. Ensuring methodological rigor will maximize the impact and reproducibility of DCE research in health economics.
Collapse
Affiliation(s)
- Sven Petrus Henricus Nouwens
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
- Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands.
- Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands.
| | - Stella Maria Marceta
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands
- Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands
- Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands
| | - Michael Bui
- Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Daisy Maria Alberta Hendrika van Dijk
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands
- Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands
- Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands
| | | | - Jorien Veldwijk
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands
- Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands
- Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands
| | - Janine Astrid van Til
- Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Esther Wilhelmina de Bekker-Grob
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands
- Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands
- Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands
| |
Collapse
|
2
|
Manipis K, Cronin P, Street D, Church J, Viney R, Goodall S. Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study. PHARMACOECONOMICS 2025; 43:453-467. [PMID: 39754692 DOI: 10.1007/s40273-024-01458-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/21/2024] [Indexed: 01/06/2025]
Abstract
BACKGROUND Cost-utility analyses commonly use two primary methods to value productivity: the human capital approach (HCA) and the friction cost approach (FCA). Another less frequently used method is the willingness-to-pay (WTP) approach, which estimates the monetary value individuals assign to avoiding an illness. In the context of foodborne illnesses (FBI), productivity loss represents one of the most significant economic impacts, particularly in developed nations. These losses arise from factors such as missed workdays, reduced workplace efficiency due to illness, and long-term health complications that can limit an individual's ability to work. As a result, accurately quantifying productivity loss is critical in understanding the broader economic burden of FBI. AIM Our aim was to compare the impact of valuation methods used to measure productivity loss in an economic evaluation, using a hypothetical intervention for FBI caused by campylobacter as a case study. Cost effectiveness from three perspectives is examined: health care system, employee, and employer. METHOD A Markov model with a 10-year time horizon was developed to evaluate the morbidity and productivity impacts of FBI caused by campylobacter. The model included four health states: 'healthy', 'acute gastroenteritis', 'irritable bowel syndrome and being unable to work some of the time', and 'irritable bowel syndrome and unable to work'. Five approaches to valuing productivity loss were compared: model 1 (cost-utility analysis), model 2 (HCA), model 3 (FCA), model 4 (FCA+WTP to avoid illness with paid sick leave), and model 5 (WTP to avoid illness without paid sick leave). Health outcomes and costs were discounted using a 5% discount rate. Costs were reported in 2024 Australian dollars ($AUD). RESULTS Model 1, which did not include productivity losses, yielded the highest incremental cost-effectiveness ratio (ICER) at $56,467 per quality-adjusted life-year (QALY) gained. The inclusion of productivity costs (models 2-5) significantly increased the total costs in both arms of the models but led to a marked reduction in the ICERs. For example, model 2 (HCA) resulted in an ICER of $11,174/QALY gained, whereas model 3 (FCA) resulted in $21,136/QALY gained. Models 4 and 5, which included WTP approaches, had ICERs of $19,661/QALY gained and $24,773/QALY gained, respectively. CONCLUSION These findings underscore the significant impact of different modelling approaches to productivity loss on ICER estimates and consequently the decision to adopt a new policy or intervention. The choice of perspective in the analysis is critical, as it determines how the short-term and long-term productivity losses are accounted for and valued. This highlights the importance of carefully selecting and justifying the perspective and valuation methods used in economic evaluations to ensure informed and balanced policy decisions.
Collapse
Affiliation(s)
- Kathleen Manipis
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia.
| | - Paula Cronin
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia
| | - Deborah Street
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia
| | - Jody Church
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia
| | - Rosalie Viney
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia
| | - Stephen Goodall
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia
| |
Collapse
|
3
|
Meng J, Yan F, Chen M, Ding Y, Feng Z, Lu W, Geng J. Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China. BMC Public Health 2025; 25:164. [PMID: 39815238 PMCID: PMC11734541 DOI: 10.1186/s12889-024-20951-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 12/03/2024] [Indexed: 01/18/2025] Open
Abstract
BACKGROUND Ensuring equal access to affordable, high-quality, and satisfied healthcare for cancer patients is a challenge worldwide. Our study aimed to investigate preferences for public health insurance coverage of new anticancer drugs among non-small cell lung cancer (NSCLC) patients in China. METHODS We identified six attributes of new anticancer drugs and adopted a Bayesian-efficient design to generate choice scenarios for a discrete choice experiment (DCE). The one-on-one, face-to-face DCE was conducted in four cities in Jiangsu Province. The mixed logit regression model was used to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity. RESULTS Data from 486 patients were available for analysis. The most valuable attribute was the out-of-pocket cost if reimbursed (RI = 32.25%), followed by extension of overall survival (RI = 15.99%), and low incidence of serious side effects (RI = 14.45%). Patients had the highest willingness to pay for the comparative 9-month' extension of overall survival. Patients with advanced NSCLC were more likely to expect new anticancer drugs could improve HRQoL (p < 0.01) and require fewer out-of-pocket costs (p < 0.01). Older patients and patients with low income cared more about the out-of-pocket costs (p < 0.001). CONCLUSION Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer.
Collapse
Affiliation(s)
- Jingyi Meng
- Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - Feifei Yan
- Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - Maochun Chen
- Department of General Surgery, Affiliated Dongtai Hospital of Nantong University, Yancheng, 224200, Jiangsu, China
| | - Yuchen Ding
- Department of Radiology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
| | - Zhe Feng
- Medical School of Nantong University, Nantong, 226001, Jiangsu, China
- Medical Records Department, Wuxi Xishan People's Hospital, Wuxi, 214105, Jiangsu, China
| | - Wenzhang Lu
- Department of Respiratory, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
| | - Jinsong Geng
- Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
| |
Collapse
|
4
|
Mostafa H, Al Dhaheri A, Feehan J, M.K.Yousif N. Assessment of consumer demographics and food safety risks associated with ready-to-eat (RTE) homemade foods purchased online in the UAE. Heliyon 2024; 10:e24624. [PMID: 38327456 PMCID: PMC10847867 DOI: 10.1016/j.heliyon.2024.e24624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 01/10/2024] [Accepted: 01/11/2024] [Indexed: 02/09/2024] Open
Abstract
In the UAE, female entrepreneurs, termed "Tajrat", sell a variety of homemade food products over online social media (OSM) platforms. Some of these food products are prepared and sold outside regulatory channels, with serious public health consequences. The study aimed to identify consumer demographics associated with purchasing of RTE, homemade food sold over in OSM platforms in the UAE and to assess the food quality by evaluating microbiological quality and fat percentage in RTE foods. A representative survey of the population of the UAE (n = 1303) was conducted, covering consumer demographics, frequency of purchase, and respondents' perception towards safety and nutritional value. 66 % of respondents were Emiratis, fifty percent of whom purchased RTE foods online. Moreover, 61 % of participants purchased from "Tajrat" via OSM as opposed to other sources. Convenience (47 %) and taste (41 %) were the main drivers for purchasing RTE homemade foods. Although 76 % of respondents have at least one member of their family considered vulnerable, the safety levels, quality, and nutritional value of such products did not carry the same significance. Microbiological analysis of 35 food samples purchased online from "Tajrat" was conducted. Listeria spp. was isolated from 22 % of the samples, 43 % showed positive Staphylococcus aureus, and 31 % of the samples had coliform bacteria. Total Fat Content of RTE homemade food samples ranged between 2.6 and 30 g/100 g which is considered high and can cause serious health issues if consumed frequently. Recommendations from this study will help policy makers and regulators in the UAE to develop and implement education strategies targeting homemade food handlers.
Collapse
Affiliation(s)
- Hussein Mostafa
- Department of Food Science, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, 15551, United Arab Emirates
- Department of Food Science and Agricultural Chemistry, McGill University, Ste Anne de Bellevue, Quebec, H9X 3V9, Canada
| | - Ayesha Al Dhaheri
- Department of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, 15551, United Arab Emirates
| | - Jack Feehan
- Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia
| | - Nuha M.K.Yousif
- Department of Food Science, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, 15551, United Arab Emirates
| |
Collapse
|
5
|
Tan S, Wang Y, Tang Y, Jiang R, Chen M, Chen H, Yang F. Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method. Front Public Health 2022; 10:1005453. [PMID: 36579068 PMCID: PMC9790908 DOI: 10.3389/fpubh.2022.1005453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 11/28/2022] [Indexed: 12/14/2022] Open
Abstract
Objectives To explore whether a societal preference for orphan drugs exists in Chinese general public and to quantitatively measure the personal trade-off between essential attributes of orphan drugs through a discrete choice experiment. Methods A labeled discrete choice experiment was employed to measure public preference. Six attributes (impact of diseases on life-years, impact of diseases on quality of life, availability of alternative drug treatments, annual cost per patient paid by medical insurance, expected increases in life-expectancy, and improvements to the quality of life) were identified through a literature review, experts' suggestions, and stakeholders' semi-structured interviews, then refined through a pre-survey. The current study used a D-efficient design to yield 27 choice sets divided into three blocks with nine questions containing the labeled treatment (either orphan drugs or common drugs). Information on sociodemographic characteristics and individual preferences was collected through a web-based questionnaire using convenience sampling. A mixed logit model was used to test societal preferences for orphan drugs over common drugs, while a binary logit model was used to measure the relative importance of each attribute in orphan drug access for the National Reimbursement Drug List and its willingness to pay. Results A total of 323 persons participated in this study. Respondents largely had indifferent attitudes toward orphan drugs and common drugs. The binary logit model results showed that 5 of the 6 attributes were significant, except for the availability of alternative drug treatments. The most impacted factor was the annual cost per patient paid by medical insurance (β = -1.734, odds ratio [OR] = 0.177). Among non-economic attributes, the impact of diseases on life-years-with no treatment, the patient will die in the prime of life (β = 0.523, OR = 1.688, willingness to pay = 301,895)-was most concerning, followed by significant improvements to the quality of life (β = 0.516, OR = 1.676, willingness to pay = 297,773). Conclusion The general public in China does not value rarity as a sufficient reason to justify special consideration in funding orphan drugs. When making orphan drug coverage decisions, the public prioritized the annual cost, disease severity, and drug effects.
Collapse
Affiliation(s)
- Shuoyuan Tan
- School of Health Policy & Management, Nanjing Medical University, Nanjing, China,Center for Global Health, Nanjing Medical University, Nanjing, China
| | - Yu Wang
- School of Health Policy & Management, Nanjing Medical University, Nanjing, China,Center for Global Health, Nanjing Medical University, Nanjing, China
| | - Yuqing Tang
- School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Rong Jiang
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China,The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing, China
| | - Mingsheng Chen
- School of Health Policy & Management, Nanjing Medical University, Nanjing, China,Center for Global Health, Nanjing Medical University, Nanjing, China
| | - Haihong Chen
- School of Health Policy & Management, Nanjing Medical University, Nanjing, China,Center for Global Health, Nanjing Medical University, Nanjing, China,*Correspondence: Haihong Chen
| | - Fan Yang
- School of Health Policy & Management, Nanjing Medical University, Nanjing, China,Center for Global Health, Nanjing Medical University, Nanjing, China,Fan Yang
| |
Collapse
|